| Literature DB >> 31252598 |
Joanna Hołowko1, Małgorzata Magdalena Michalczyk2, Adam Zając3, Maja Czerwińska-Rogowska1, Karina Ryterska1, Marcin Banaszczak1, Karolina Jakubczyk1, Ewa Stachowska1.
Abstract
OBJECTIVE: The aim of the study was to compare the impact of 6 weeks of reducing daily caloric intake by 20% of total daily energy expenditure (TDEE)-CRI vs. reducing daily caloric intake by 30% of TDEE-CRII on body mass reduction and insulin metabolism in former athletes.Entities:
Keywords: IGF-1; adiponectin; body mass reduction; calorie restriction diet; insulin; leptin
Mesh:
Substances:
Year: 2019 PMID: 31252598 PMCID: PMC6683015 DOI: 10.3390/nu11071461
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of the applied diets.
| Nutrients | CR I | CR II |
|---|---|---|
| TEI, kJ | 9589.73 ± 150.6 | 8924.48 ± 217.6 |
| TEI, kcal | 2292 ± 36 | 2133 ± 52 |
| CARBOHYDRATES, % | 50 ± 0.4 | 50 ± 0.2 |
| CARBOHYDRATES, g/kg/body mass | 2.7 ± 0.3 | 2.6 ± 0.5 |
| SIMPLE SUGARS, % | <10 | <10 |
| FIBER, g/day | 33 ± 0.2 | 34 ± 0.5 |
| FAT, % | 30 ± 0.6 | 30 ± 0.8 |
| FAT, g/kg body mass | 0.8 ± 0.2 | 0.75 ± 0.3 |
| CHOLESTEROL, mg/day | 300 ± 2.1 | 300 ± 1.7 |
| PROTEIN, % | 20 ± 0.7 | 20 ± 0.06 |
| PROTEIN, g/kg body mass | 1.2 ± 0.6 | 1.1 ± 0.4 |
Note: TEI—Total Energy Intake.
Figure 1Scheme of the experimental protocol.
The anthropometrics characteristic of the participant at the baseline.
| Variable | CRI, | CR II, |
|---|---|---|
| BM, kg | 92.3 ± 11.5 | 89.5 ± 14.0 |
| BMI | 28.1 ± 4.2 | 28.3 ± 4.1 |
| BF, % | 30.4 ± 8.0 | 29.3 ± 8.2 |
| FFM, % | 62.84 ± 8.36 | 58.98 ± 16.34 |
| FFM, kg | 67.68 ± 4.77 | 63.47 ± 17.48 |
| MM, % | 49.13 ± 4.59 | 43.36 ± 11.34 |
| TBW, % | 45.24 ± 5.26 | 42.35 ± 11.57 |
Note: CR—calorie restriction, BM—body mass; BMI—body mass index, BF—body fat, FFM—free fat mass, MM—muscle mass, TBW—total body water.
Results of Shapiro-Wilk tests for CR I and CR II.
| Variables | Shapiro-Wilk Test | |
|---|---|---|
| CR I | CR II | |
| BM, kg | 0.756 | 0.767 |
| BMI | 0.687 | 0.707 |
| BF, % | 0.686 | 0.715 |
| FFM, % | 0.713 | 0.743 |
| FFM, kg | 0.730 | 0.760 |
| MM, % | 0.749 | 0.778 |
| TBW, % | 0.764 | 0.791 |
| GL, mmol/L | 0.792 | 0.817 |
| TCh, mg/dL | 0.805 | 0.828 |
| HDL, mg/dL | 0.814 | 0.837 |
| LDL, mg/dL | 0.825 | 0.846 |
| TG, mg/dL | 0.835 | 0.855 |
| TL, mg/dL | 0.844 | 0.863 |
| I, mg/dL | 0.851 | 0.869 |
| HOMA-IR | 0.858 | 0.874 |
| Leptin, ng/mL | 0.791 | 0.813 |
| Adiponectin, ng/mL | 0.815 | 0.833 |
| IGF-1, ng/mL | 0.818 | 0.841 |
Differences in body composition, lipid profile and glucose control variables before and after CRI and CRII diet.
| Variable | CR I | CR II | ||||||
|---|---|---|---|---|---|---|---|---|
| Before | After | ES | Before | After | ES | ES CR II vs. CR I | ||
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||||
| Body composition | BM, kg | 92.3 ± 11.5 | 90.4 ± 10.7 | 0.014 | 89.5 ± 14.0 | 87.1 ± 12.6 | 0.031 | 0.037 |
| BMI | 28.1 ± 4.2 | 27.8 ± 3.7 | 0.011 | 28.3 ± 4.1 | 27.3 ± 4.0 | 0.010 | 0.011 | |
| BF, % | 30.4 ± 8.0 | 29.2 ± 5.8 | 0.013 | 30.71 ± 5.9 | 29.0 ± 7.7 | 0.027 | 0.014 | |
| FFM, kg | 62.84 ± 8.36 | 58.95 ± 7.26 | 0.015 | 59.98 ± 16.34 | 58.02 ± 14.82 | 0.024 | 0.012 | |
| FFM, % | 67.68 ± 4.77 | 67.62 ± 4.95 | 0.010 | 66.39 ± 14.10 | 63.47 ± 17.48 | 0.055 | 0.045 | |
| MM, % | 49.13 ± 4.59 | 48.70 ± 6.07 | 0.011 | 48.39 ± 12.62 | 43.36 ± 11.34 | 0.058 | 0.051 | |
| TBW, kg | 45.24 ± 5.26 | 45.18 ± 4.83 | 0.010 | 43.95 ± 11.80 | 42.35 ± 11.57 | 0.026 | 0.034 | |
| Lipid profile | tCh, mg/dL | 197.2 ± 40.3 | 171.4 ± 53.4 * | 0.343 * | 198.1 ± 40.5 | 187.3 ± 37.1 #* | 0.241 | 0.351 #* |
| HDL, mg/dL | 51.6 ± 13.4 | 47.0 ± 16.2 | 0.061 | 54.7 ± 13.3 | 56.4 ± 17.9 | 0.021 | 0.061 | |
| LDL, mg/dL | 107.6 ± 28.3 | 102.5 ± 64.7 | 0.072 | 122.8 ± 42.0 | 116.3 ± 34.8 #* | 0.253 | 0.347 #* | |
| TG, mg/dL | 102.3 ± 57.3 | 89.7 ± 54.8 * | 0.333 | 108.5 ± 45.8 | 83.0 ± 48.7 * | 0.249 * | 0.057 | |
| TL, mg/dL | 599.51 ± 102.7 | 520.80 ± 105.1 * | 0.349 * | 630.44 ± 124.4 | 572.93 ± 97.3 * | 0.135 * | 0.355 | |
| Glucose control | GL, mmol/L | 5.24 ± 0.83 | 4.86 ± 1.27 | 0.070 | 5.34 ± 1.53 | 5.17 ± 1.01 | 0.013 | 0.067 |
| I, mg/dL | 10.9 ± 6.9 | 8.7 ± 5.2 | 0.034 | 10.0 ± 8.2 | 9.06 ± 5.8 | 0.021 | 0.028 | |
| HOMA-IR | 2.6 ± 2.3 | 2.4 ± 1.1 | 0.010 | 2.7 ± 1.3 | 2.0 ± 1.4 | 0.010 | 0.012 | |
| Leptin, ng/mL | 13.78 ± 4.8 | 9.45 ± 6.9 * | 0.148 * | 13.27 ± 4.7 | 9.69 ± 3.9 * | 0.144 * | 0.019 | |
| Adiponectin, ng/mL | 3.33 ± 1.3 | 7.10 ± 3.2 * | 0.166 * | 3.83 ± 1.2 | 6.93 ± 3.3 * | 0.147 * | 0.022 | |
| IGF-1, ng/mL | 43.93 ± 4.6 | 42.50 ± 14.8 | 0.041 | 44.76 ± 10.4 | 42.93 ± 6.6 | 0.023 | 0.011 | |
Note: ES—effect size, BM—body mass; BMI—body mass index, BF—body fat, FFM—free fat mass, MM—muscle mass, TBW—total body water, TL—total lipids, TG—triglycerides, tCh—total cholesterol, HDL—cholesterol HDL, LDL—cholesterol LDL, GL—glucose, I—insulin, IGF-1—insulin-like growth factor, *—statistically significant difference with p < 0.01 compared with before and ES for after, #—statistically significant difference with p < 0.05 compared with the CRI and ES for CRII; #*—statistically significant difference with p < 0.05 compared with the CRI and ES for CRII and after.
Results of the CR I and CR II diet on body mass and composition before and after the diet intervention.
|
|
| |||||
|
|
|
| ||||
|
|
|
|
|
|
| |
| BM, Kg | 97.95 ± 4.5 | 92.26 ± 3.1 | 99.60 ± 6.1 | 94.75 ± 4.2 | 105.67 ± 5.2 | 100.91 ± 8.1 |
| BMI | 31.26 ± 1.2 | 28.14 ± 0.2 | 30.65 ± 2.13 | 29.23 ± 1.3 | 32.19 ± 2.5 | 30.86 ± 2.1 |
| BF, % | 30.68 ± 3.1 | 29.92 ± 2.1 | 32.46 ± 5.3 | 31.85 ± 3.4 | 37.61 ± 3.4 | 37.10 ± 5.3 |
| FFM, % | 69.32 ± 4.2 | 68.05 ± 3.64 | 67.60 ± 4.2 | 66.54 ± 5.3 | 63.02 ± 4.2 | 62.39 ± 5.2 |
| FFM, Kg | 59.52 ± 3.1 | 55.75 ± 2.36 * | 60.70 ± 4.1 | 55.91 ± 4.2 | 55.94 ± 4.1 | 53.53 ± 2.5 |
| MM, % | 49.97 ± 5.3 | 46.91 ± 2.77 * | 49.56 ± 3.1 | 46.97 ± 2.7 | 42.96 ± 2.6 | 42.67 ± 2.9 |
| TBW, % | 50.87 ± 5.3 | 49.19 ± 3.36 | 49.61 ± 4.2 | 48.55 ± 3.1 | 47.59 ± 3.9 | 46.84 ± 2.8 |
|
|
| |||||
|
|
|
| ||||
|
|
|
|
|
|
| |
| BM, Kg | 96.95 ± 8.9 | 93.37 ± 6.3 | 100.43 ± 4.2 | 96.27 ± 4.3 | 98.67 ± 3.8 | 93.15 ± 2.1 |
| BMI | 30.08 ± 1.3 | 28.99 ± 1.4 | 30.78 ± 2.1 | 29.56 ± 1.1 | 30.40 ± 2.1 | 28.30 ± 1.4 |
| BF, % | 32.89 ± 2.1 | 31.86 ± 2.4 | 34.44 ± 2.6 | 33.75 ± 1.3 | 33.61 ± 2.1 # | 31.21 ± 0.9 # |
| FFM, % | 67.60 ± 3.1 | 65.84 ± 4.2 | 65.56 ± 4.2 | 65.21 ± 3.8 | 68.79 ± 4.9 # | 67.90 ± 5.3 |
| FFM, Kg | 58.48 ± 4.1 | 57.86 ± 3.2 | 58.53 ± 3.6 | 55.98 ± 4.1 | 59.71 ± 3.2 | 54.86 ± 3.1 |
| MM, % | 47.83 ± 2.1 | 46.92 ± 3.5 | 46.83 ± 2.6 | 44.74 ± 2.5 | 49.86 ± 2.1 # | 46.64 ± 2.5 |
| TBW, % | 50.25 ± 4.1 | 48.86 ± 3.4 | 48.85 ± 3.6 | 47.82 ± 4.1 | 50.59 ± 3.2 # | 48.56 ± 3.5 |
Note: BM—body mass; BMI—body mass index, BF—body fat, FFM—free fat mass, MM—muscle mass, TBW—total body water, *—statistically significant difference with p < 0.05 compared with baseline, #—statistically significant difference with p < 0.05 compared with the CRI.
Results of the CR I and CR II diet on lipid profile and glucose control variables before and after the diet intervention in particular subgroups.
|
|
| ||||||
|
|
|
| |||||
|
|
|
|
|
|
| ||
| Lipid profile | TL, mg/dL | 735.63 ± 33.5 | 609.65 ± 41.23 | 775.00 ± 47.3 | 665.36 ± 63.1 | 608.86 ± 51.3 | 528.50 ± 72.1 |
| TG, mg/dL | 131.63 ± 13.37 | 84.41 ± 14.91 * | 127.30 ± 8.2 | 84.45 ± 13.1 | 126.00 ± 11.2 | 82.63 ± 8.2 | |
| tCh, mg/dL | 201.56 ± 35.26 | 162.35 ± 26.13 | 200.90 ± 26.1 | 166.55 ± 21.4 | 181.14 ± 38.5 | 165.00 ± 27.2 | |
| LDL, mg/dL | 132.25 ± 14.81 | 104.47 ± 12.1 | 139.90 ± 12.5 | 110.45 ± 9.2 | 120.86 ± 17.1 | 99.87 ± 15.5 | |
| HDL, mg/dL | 49.81 ± 2.94 | 49.12 ± 3.2 | 46.37 ± 5.3 | 47.62 ± 8.2 | 49.43 ± 3.2 | 50.07 ± 4.1 | |
| Glucose control | GL, mmol/L | 5.30 ± 1.42 | 4.78 ± 0.6 | 5.50 ± 0.8 | 4.95 ± 1.7 | 5.51 ± 1.5 | 5.12 ± 1.2 |
| I, mg/dL | 11.08 ± 2.62 | 10.14 ± 1.3 | 13.52 ± 4.1 | 12.86 ± 3.1 | 11.79 ± 3.7 | 10.18 ± 4.2 | |
| HOMA-IR | 2.68 ± 0.31 | 2.43 ± 0.24 | 3.36 ± 1.3 | 3.15 ± 1.5 | 2.82 ± 0.8 | 2.36 ± 0.7 | |
| Leptin, ng/mL | 12.32 ± 1.2 | 9.76 ± 1.3 * | 13.10 ± 1.4 | 8.45 ± 0.4 * | 15.43 ± 2.3 | 9.19 ± 1.3 * | |
| Adiponectin, ng/mL | 3.51 ± 0.2 | 6.45 ± 0.5 * | 3.50 ± 0.3 | 7.55 ± 0.5 * | 3.12 ± 0.6 | 7.20 ± 1.2 * | |
| IGF-1, ng/mL | 42.23 ± 0.9 | 41.90 ± 2.1 | 43.06 ± 1.1 | 41.60 ± 0.8 | 44.21 ± 3.4 | 43.10 ± 1.5 | |
|
|
| ||||||
|
|
|
| |||||
|
|
|
|
|
|
| ||
| Lipid profile | TL, mg/dL | 639.71 ± 42.3 | 559.36 ± 23.2 * | 632.70 ± 54.2 | 540.40 ± 21.1 * | 649.14 ± 32.1 | 548.57 ± 24.5 * |
| TG, mg/dL | 99.50 ± 4.2 | 71.36 ± 12.1 | 109.00 ± 12.3 | 76.70 ± 21.5 | 109.00 ± 15.1 | 73.86 ± 23.6 | |
| tCh, mg/dL | 204.54 ± 18.1 | 183.64 ± 13.1 * | 199.40 ± 14.2 | 172.80 ± 11.2 * | 206.71 ± 14.1 # | 177.57 ± 12.2 * | |
| HDL, mg/dL | 55.50 ± 8.2 | 56.63 ± 6.1 | 50.80 ± 3.1 | 49.89 ± 4.1 | 50.42 ± 4.1 | 50.76 ± 3.4 | |
| LDL, mg/dL | 131.43 ± 9.4 | 112.64 ± 7.3 * | 126.90 ± 8.2 | 107.60 ± 8.2 * | 134.5 ± 7.27 | 112.29 ± 9.4 * | |
| Glucose control | GL, mmol/L | 5.07 ± 1.1 | 5.04 ± 0.8 | 5.34 ± 0.7 | 5.12 ± 0.9 | 5.39 ± 0.8 | 5.10 ± 1.1 |
| I, mg/dL | 10.77 ± 1.8 | 8.34 ± 1.3 | 12.29 ± 1.3 | 8.72 ± 2.8 | 14.99 ± 2.1 | 9.90 ± 3.1 | |
| HOMA-IR | 2.52 ± 0.5 | 1.93 ± 0.9 | 2.91 ± 0.7 | 2.13 ± 0.5 | 3.57 ± 1.4 | 2.46 ± 1.1 | |
| Leptin, ng/mL | 11.86 ± 2.1 | 8.13 * ± 2.5 | 12.10 ± 3.1 | 9.65 * ± 0.3 | 15.15 ± 1.1 | 10.30 * ± 1.2 | |
| Adiponectin, ng/mL | 4.08 ± 1.2 | 8.10 * ± 2.6 | 3.84 ± 3.2 | 7.20 * ± 0.4 | 3.60 ± 0.8 | 6.95 * ± 0.4 | |
| IGF-1, ng/mL | 44.35 ± 2.7 | 43.16 ± 3.1 | 42.94 ± 2.9 | 43.08 ± 1.5 | 42.40 ± 1.9 | 41.30 ± 0.8 | |
Note: TL—total lipids, TG—triglycerides, tCh—total cholesterol, HDL—cholesterol HDL, LDL—cholesterol LDL, GL—glucose, I—insulin, IGF-1—insulin-like growth factor, *—statistically significant difference with p < 0.05 compared with baseline, #—statistically significant difference with p < 0.05 compared with the CRI.